Siying Li | Cardiovascular diseases | Best Researcher Award

Dr. Siying Li | Cardiovascular diseases | Best Researcher Award

Dr. Siying Li, Central Hospital affiliated to Shandong First Medical University, China

Dr. Siying Li is an Associate Research Fellow at the Metabolism and Disease Research Center, Central Hospital affiliated with Shandong First Medical University, China. She holds a Ph.D., M.M., and M.B. from Shandong University and has conducted postdoctoral research in cardiometabolic diseases. Her work focuses on hydrogen sulfide regulation in mitochondria, autophagy in heart failure, and ferroptosis in metabolic disorders. With experience as a Visiting Scholar at the University of South Carolina, U.S., she has contributed significantly to medical research. Her findings have been widely recognized, making her a leading researcher in metabolism and cardiovascular health.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Dr. Siying Li’s academic journey is marked by excellence and dedication to medical research. She earned her Ph.D. (2010-2015), M.M. (2009-2010), and M.B. (2003-2009) from Shandong University, China, a prestigious institution known for its contributions to medical science. Her strong academic foundation laid the groundwork for her specialization in metabolism and disease research, with a keen focus on cardiometabolic disorders.

💼 PROFESSIONAL ENDEAVORS:

Dr. Li’s career progression reflects her commitment to medical research and academia. She is currently an Associate Research Fellow at the Metabolism and Disease Research Center, Central Hospital affiliated with Shandong First Medical University (2023-Present). Previously, she held key research positions, including:
🔹 Associate Research Fellow at the Shandong Institute of Endocrine and Metabolic Disease (2021-2023)
🔹 Assistant Research Fellow at the Department of Pathophysiology, School of Basic Medicine, Shandong University (2017-2020)
🔹 Postdoctoral Researcher at Shandong University (2015-2017)
🔹 Visiting Scholar at the University of South Carolina, U.S. (2011-2013)

Her extensive experience in both national and international institutions has provided her with a global perspective on medical research, fostering interdisciplinary collaborations.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR DISEASES:

Dr. Li’s research is centered on cardiometabolic diseases, an area of growing significance in modern medicine. Her key research contributions include:
Hydrogen Sulfide & Mitochondria in Heart Failure – Investigating its regulatory role in cellular metabolism and autophagy.
Iron Metabolism & Ferroptosis in Cardiometabolic Diseases – Exploring its potential in disease progression and therapeutic interventions.

Her work has advanced the understanding of molecular mechanisms in cardiovascular health, paving the way for potential breakthroughs in medical treatments.

🌍 IMPACT AND INFLUENCE:

Dr. Li’s research has made a significant impact on the global scientific community, particularly in the fields of metabolism, endocrinology, and cardiovascular health. Her studies on ferroptosis and hydrogen sulfide regulation have influenced new treatment approaches for heart failure and metabolic disorders. Her collaborations with leading research institutions and hospitals have further amplified the clinical relevance of her findings.

📚 ACADEMIC CITATIONS AND RECOGNITION:

Dr. Li’s work has been widely recognized in peer-reviewed journals and international conferences. Her research has garnered numerous citations, reflecting its significance and contribution to the medical field. She has also actively participated in academic symposiums and medical panels, sharing her insights with researchers worldwide.

🚀 LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Li’s ongoing research promises to make groundbreaking contributions to medicine. Her expertise in molecular metabolism and cardiovascular pathophysiology positions her as a key figure in the future of personalized medicine and targeted therapies. Her dedication to advancing scientific knowledge and mentoring young researchers ensures a lasting impact on the field of medical science.

🏅 CONCLUSION:

Dr. Siying Li is a distinguished researcher whose contributions to cardiometabolic diseases have significantly advanced medical science. Her expertise in hydrogen sulfide regulation, mitochondrial function, and ferroptosis has provided valuable insights into heart failure and metabolic disorders. With a strong academic background, extensive research experience, and international collaborations, she has established herself as a leading scientist in her field. Her work not only enhances fundamental understanding but also paves the way for innovative therapeutic approaches.

TOP NOTABLE PUBLICATIONS

The potential role of hydrogen sulfide in regulating macrophage phenotypic changes via PINK1/parkin-mediated mitophagy in sepsis-related cardiorenal syndrome

Authors: Chen, Y., Cao, W., Li, B., … Yang, G., Li, S.

Journal: Immunopharmacology and Immunotoxicology

Year: 2024

Cyclophilin D as a potential therapeutic target of liver ischemia/reperfusion injury by mediating crosstalk between apoptosis and autophagy

Authors: Yang, M., Wang, Z., Xie, J., … Li, S., Song, Y.

Journal: Chronic Diseases and Translational Medicine

Year: 2023

 Urine proteomics for profiling of mouse toxoplasmosis using liquid chromatography tandem mass spectrometry analysis

Authors: Cui, L.-L., Zhou, C.-X., Han, B., … Xie, S.-C., Zhou, D.-H.

Journal: Parasites and Vectors

Year: 2021

S-allylmercaptocysteine ameliorates lipopolysaccharide-induced acute lung injury in mice by inhibiting inflammation and oxidative stress via nuclear factor kappa B and Keap1/Nrf2 pathways

Authors: Mo, M., Li, S., Dong, Z., … Li, A., Zhao, Z.

Journal: International Immunopharmacology

Year: 2020

The key role of macrophage depolarization in the treatment of COPD with ergosterol both in vitro and in vivo

Authors: Sun, X., Liu, Y., Feng, X., … Li, S., Zhao, Z.

Journal: International Immunopharmacology

Year: 2020

S-allylmercaptocysteine targets NRF2 in osteoarthritis treatment through NOX4/NF-ΚB pathway

Authors: Yang, G., Sun, S., Wang, J., … Yuan, L., Li, S.

Journal: Drug Design, Development and Therapy

Year: 2020

 A nucleoside/nucleobase-rich extract from Cordyceps sinensis inhibits the epithelial-mesenchymal transition and protects against renal fibrosis in diabetic nephropathy

Authors: Dong, Z., Sun, Y., Wei, G., Li, S., Zhao, Z.

Journal: Molecules

Year: 2019

Ergosterol attenuates cigarette smoke extract-induced COPD by modulating inflammation, oxidative stress and apoptosis in vitro and in vivo

Authors: Sun, X., Feng, X., Zheng, D., … Li, S., Zhao, Z.

Journal: Clinical Science

Year: 2019

 Yifei tongluo, a Chinese herbal formula, suppresses tumor growth and metastasis and exerts immunomodulatory effects in Lewis lung carcinoma mice

Authors: Qi, Q., Hou, Y., Li, A., … Li, S., Zhao, Z.

Journal: Molecules

Year: 2019

Ergosterol ameliorates diabetic nephropathy by attenuating mesangial cell proliferation and extracellular matrix deposition via the TGF-β1/Smad2 signaling pathway

Authors: Dong, Z., Sun, Y., Wei, G., Li, S., Zhao, Z.

Journal: Nutrients

Year: 2019

Ron Waksman | Cardiology | Best Researcher Award

Dr. Ron Waksman | Cardiology | Best Researcher Award

👨‍⚕️Dr. Ron Waksman, MedStar Health, United States

Dr. Ron Waksman is a prominent figure in the field of cardiology, currently serving as the Director of Cardiovascular Research and Advanced Education at MedStar Heart & Vascular Institute. With an academic background spanning multiple continents, he has established himself as a leading expert in interventional cardiology and cardiovascular research. His vast professional journey reflects a dedication to advancing cardiovascular medicine and educating future generations of physicians.

Author Professional Profile

Scopus

Google Scholar

Evaluation of Ron Waksman, MD, FACS for the Best Researcher Award

Summary of Suitability

Dr. Ron Waksman is an outstanding candidate for the Best Researcher Award. His unparalleled contributions to cardiovascular medicine through research, clinical innovation, and academic leadership are well-aligned with the criteria for this recognition. His legacy of impactful work and dedication to advancing the field make him a deserving recipient of this prestigious award.

EARLY ACADEMIC PURSUITS 🎓

Dr. Waksman’s academic journey began at the Hebrew University in Jerusalem, where he earned his Bachelor of Science in Statistics, Economics, and Business Administration in 1975. His medical education continued at Ben Gurion University in Beer-Sheva, Israel, where he graduated with a Medical Degree (MD) in 1981. His commitment to further specialization led him to multiple prestigious institutions for residency and fellowships, including Emory University and Hadassah University Hospital.

PROFESSIONAL ENDEAVORS 💼

Dr. Waksman’s professional career includes significant roles in both academic and clinical settings. He has been a clinical professor of medicine at Georgetown University since 2001 and has served as the Associate Director of the Division of Cardiology at MedStar Washington Hospital Center. His leadership in cardiovascular research and innovation is showcased through his role in pioneering experimental angioplasty and advancing new technologies in cardiovascular care.

ACADEMIC CITES 🔬

Dr. Waksman’s impact on cardiology extends beyond clinical practice, with numerous publications in top-tier journals. He has been recognized for his contributions to advancing interventional cardiology, particularly in areas of experimental angioplasty, vascular brachytherapy, and innovative cardiovascular therapies. He also serves on several editorial boards and holds the position of Editor-in-Chief for Cardiovascular Revascularization Medicine.

CONTRIBUTIONS AND RESEARCH FOCUS ON Cardiology 🔍

Dr. Waksman’s research has contributed to many groundbreaking studies in cardiovascular medicine. His role as a principal investigator in numerous pivotal clinical trials, such as IRIS and WRIST, has helped shape the landscape of interventional cardiology. His research interests include enhancing the outcomes of angioplasty, improving cardiovascular device technologies, and exploring new therapies for vascular diseases.

IMPACT AND INFLUENCE 🌍

Dr. Waksman’s influence is felt across the global cardiology community. Through his extensive clinical experience and research contributions, he has become a mentor and educator, shaping the future of interventional cardiology. His work has had a lasting impact on medical practice and patient outcomes, especially in the areas of heart disease and vascular interventions.

LEGACY AND FUTURE CONTRIBUTIONS ⏳

Dr. Waksman’s legacy will be defined by his contributions to cardiovascular research, education, and innovation. His work continues to inspire the next generation of cardiologists, and his future contributions will likely focus on advancing minimally invasive techniques and developing novel therapies for cardiovascular diseases. His leadership in clinical trials will ensure that his influence remains strong in shaping the future of interventional cardiology.

CONCLUSION 🏁

Dr. Ron Waksman stands as a leader in the field of cardiology, with a distinguished career spanning education, research, and clinical practice. His dedication to improving patient care, advancing medical knowledge, and educating future cardiologists ensures his lasting impact on the field. As he continues his work, Dr. Waksman’s contributions will no doubt shape the future of cardiovascular medicine for years to come.

NOTABLE TOP PUBLICATIONS 📖

Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy
  • Authors: EP McFadden, E Stabile, E Regar, E Cheneau, ATL Ong, T Kinnaird, …
    Journal: The Lancet
    Year: 2004

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate

  • Authors: L Bonello, US Tantry, R Marcucci, R Blindt, DJ Angiolillo, R Becker, …
    Journal: Journal of the American College of Cardiology
    Year: 2010
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants
  • Authors: Schwartz Stephen M, Siscovick David S, …
    Journal: Nature Genetics
    Year: 2009
Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial
  • Authors: R Erbel, C Di Mario, J Bartunek, J Bonnier, B de Bruyne, FR Eberli, P Erne, …
    Journal: The Lancet
    Year: 2007
Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding
  • Authors: US Tantry, L Bonello, D Aradi, MJ Price, YH Jeong, DJ Angiolillo, …
    Journal: Journal of the American College of Cardiology
    Year: 2013
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents
  • Authors: PK Kuchulakanti, WW Chu, R Torguson, P Ohlmann, SW Rha, LC Clavijo, …
    Journal: Circulation
    Year: 2006
The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox?
  • Authors: L Gruberg, NJ Weissman, R Waksman, S Fuchs, R Deible, EE Pinnow, …
    Journal: Journal of the American College of Cardiology
    Year: 2002
Transcatheter aortic valve implantation in failed bioprosthetic surgical valves
  • Authors: D Dvir, JG Webb, S Bleiziffer, M Pasic, R Waksman, S Kodali, M Barbanti, …
    Journal: JAMA
    Year: 2014
Intracoronary γ-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis
  • Authors: R Waksman, RL White, RC Chan, BG Bass, L Geirlach, GS Mintz, …
    Journal: Circulation
    Year: 2000
Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies
  • Authors: AJ Kirtane, A Gupta, S Iyengar, JW Moses, MB Leon, R Applegate, …
    Journal: Circulation
    Year: 2009